Expertise in
25
conditions

Dr. Robert A. Baiocchi

Hematology | Oncology
Osu Internal Medicine LLC
460 W 10th Ave, 
Columbus, OH 
Accepting New Patients
Expertise in
25
conditions
Osu Internal Medicine LLC
460 W 10th Ave, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Baiocchi is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Baiocchi is highly rated in 25 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Baiocchi is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

OSU INTERNAL MEDICINE LLC
460 W 10th Ave, Columbus, OH 43210
Other Locations
OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Early Phase 1
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: September 23, 2024
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 1
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Lenalidomide
Study Phase: Phase 1
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

138 Total Publications

Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma.
Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma.
Journal: Blood advances
Published: December 30, 2024
Similar Doctors
Expertise in
44
conditions
Dr. Spero R. Cataland
Hematology | Oncology | Hematology Oncology
Expertise in
44
conditions
Dr. Spero R. Cataland
Hematology | Oncology | Hematology Oncology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
 (0.1 mi)
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Spero Cataland is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Cataland is highly rated in 44 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy. Dr. Cataland is currently accepting new patients.

Steven M. Devine
Expertise in
20
conditions
Dr. Steven M. Devine
Hematology | Oncology
Expertise in
20
conditions
Dr. Steven M. Devine
Hematology | Oncology
320 W 10th Ave, B316 Starling Loving Hall, 
Columbus, OH 
 (0.2 mi)
614-293-3316
Languages Spoken:
English
See accepted insurances

Steven Devine is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Devine is highly rated in 20 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

Uma M. Borate
Expertise in
14
conditions
Dr. Uma M. Borate
Hematology | Hematology Oncology | Oncology
Expertise in
14
conditions
Dr. Uma M. Borate
Hematology | Hematology Oncology | Oncology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (0.1 mi)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Uma Borate is a Hematologist and a Hematologist Oncology provider in Columbus, Ohio. Dr. Borate is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Borate is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baiocchi's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile